Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.

Cells - 4 Dec 2020

Swayden Mirna, Chhouri Houssein, Anouar Youssef, Grumolato Luca

Abstract excerpt

The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant/persister cells that survive in the presence of the treatment. Different processes contribute to the emergence of these cells, including pathway rebound through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Transcriptome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33291749
DOI: 10.3390/cells9122601
PMCID: PMC7761971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.PMID 33291749Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for TherapySemantic proximity Read ↗

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesSemantic proximity Read ↗

Drug-Tolerant Persister Cells in Cancer Therapy ResistanceSemantic proximity Read ↗

Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor MicroenvironmentSemantic proximity Read ↗

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read ↗

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapiesSemantic proximity Read ↗

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancerSemantic proximity Read ↗

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read ↗

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistanceSemantic proximity Read ↗

Gene Panel of Persister Cells as a Prognostic Indicator for Tumor Repopulation After RadiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.